Respiratory syncytial virus-associated mortality in hospitalized infants and young children

Pediatrics

Volumn 135, Issue 1, 2015, Pages e24-e31

  Byington, Carrie L ^a   Wilkes, Jacob ^b   Korgenski, Kent ^b   Sheng, Xiaoming ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CHILD HOSPITALIZATION; CHILDHOOD MORTALITY; CHRONIC DISEASE; HOSPITALIZED CHILD; HOSPITALIZED INFANT; HUMAN; INFANT; INFANT MORTALITY; LENGTH OF STAY; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEASONAL VARIATION; SEPSIS; UNITED STATES; VIRAL BRONCHIOLITIS; VIRUS PNEUMONIA; HOSPITAL MORTALITY; MORTALITY; NEWBORN;

HOSPITAL MORTALITY; HUMANS; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 84920405800     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-2151     Document Type: Article

References (30)

1. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543-546
2. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598
3. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2): 179-186
4. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitisassociated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis. 2001;183(1):16-22
5. Institute of Medicine. The prospects for immunizing against respiratory syncytial virus. New Vaccine Development: Establishing Priorities. Vol. 1. Washington, DC: National Academies Press; 1986;397-409
6. Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA Jr. Trends in bronchiolitis hospitalizations in the United States, 2000-2009. Pediatrics. 2013;132(1):28-36
7. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4:CD006602
8. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2): 415-420
9. Healthcare Cost and Utilization Project. Kids' Inpatient Database, 2000. Rockville, MD: Agency for Health Care Research and Quality; 2003
10. Healthcare Cost and Utilization Project. Kids' Inpatient Database 2003. Rockville, MD: Agency for Health Care Research and Quality; 2005
11. Healthcare Cost and Utilization Project. Kids Inpatient Database 2006. Rockville, MD: Agency for Health Care Research and Quality; 2008
12. Healthcare Cost and Utilization Project. Kids' Inpatient Database 2011. Rockville, MD: Agency for Health Care Research and Quality; 2011
13. Kittle K, Currier K, Dyk L, Newman K. Using a pediatric database to drive quality improvement. Semin Pediatr Surg. 2002;11(1):60-63
14. Stempel HE, Martin ET, Kuypers J, Englund JA, Zerr DM. Multiple viral respiratory pathogens in children with bronchiolitis. Acta Paediatr. 2009;98(1): 123-126
15. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54(10):1427-1436
16. Healthcare Cost and Utilization Project. Overview of the Kids' Inpatient Database (KID). Available at: www.hcup-us.ahrq.gov/kidoverview.jsp. Accessed September 26, 2014
17. Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J. 2011; 30(6):510-517
18. Children's Hospital Association. PHIS+: augmenting the Pediatric Health Information System with clinical data. Available at: www.childrenshospitals.org/phisplus/index.html. Accessed September 26, 2014
19. Feudtner C, Hays RM, Haynes G, Geyer JR, Neff JM, Koepsell TD. Deaths attributed to pediatric complex chronic conditions: national trends and implications for supportive care services. Pediatrics. 2001;107(6). Available at: www.pediatrics.org/cgi/content/full/107/6/e99
20. Li J, Monuteaux MC, Bachur RG. Interfacility transfers of noncritically ill children to academic pediatric emergency departments. Pediatrics. 2012;130(1):83-92
21. Berry JG, Hall M, Hall DE, et al. Inpatient growth and resource use in 28 children's hospitals: a longitudinal, multi-institutional study. JAMA Pediatr. 2013; 167(2):170-177
22. Centers for Disease Control and Prevention. FluView. Influenza-associated pediatric mortality. Available at: http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html. Accessed September 26, 2014
23. Horbar JD, Carpenter JH, Badger GJ, et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. Pediatrics. 2012;129(6):1019-1026
24. Sandweiss DR, Mundorff MB, Hill T, et al. Decreasing hospital length of stay for bronchiolitis by using an observation unit and home oxygen therapy. JAMA Pediatr. 2013;167(5):422-428
25. Melero JA, Moore ML. Influence of respiratory syncytial virus strain differences on pathogenesis and immunity. Curr Top Microbiol Immunol. 2013;372:59-82
26. Pretorius MA, van Niekerk S, Tempia S, et al; SARI Surveillance Group. Replacement and positive evolution of subtype A and B respiratory syncytial virus G-protein genotypes from 1997-2012 in South Africa. J Infect Dis. 2013;208(suppl 3):S227-S237
27. Winterstein AG, Knox CA, Kubilis P, Hampp C. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderatepreterm infants: a cohort study. JAMA Pediatr. 2013;167(12):1118-1124
28. Mohan AK, Braun MM, Ellenberg S, Hedje J, Coté TR. Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities. Pediatr Infect Dis J. 2004; 23(4):342-345
29. Turner TL, Kopp BT, Paul G, Landgrave LC, Hayes D Jr, Thompson R. Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res. 2014;6: 217-225
30. Hall CB, SimTes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:39-57